Thomas A. Engler

Orally Bioavailable GSK-3α/β Dual Inhibitor Increases Markers of Cellular Differentiation In Vitro and Bone Mass In Vivo

Nalini H. Kulkarni, Jude E. Onyia, Qingqiang Zeng et al. · Journal of Bone and Mineral Research · 2006 · 181 citations · Full text

Medicine, Endocrinology, Bone Metabolism +15

Total synthesis of (.+-.)-retigeranic acid

E. J. Corey, Manoj C. Desai, Thomas A. Engler · Journal of the American Chemical Society · 1985 · 110 citations

Natural Sciences, Biochemistry, Chemistry +7

Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma – Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3

Jennifer M. Atkinson, Kenneth B. Rank, Yi Arial Zeng et al. · PLoS ONE · 2015 · 107 citations · Full text

Medicine, Oncology, Pharmacology +17

Substituted 3-Imidazo[1,2-<i>a</i>]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino- [6,7,1-<i>hi</i>]indol-7-yl)pyrrole-2,5-diones as Highly Selective and Potent Inhibitors of Glycogen Synthase Kinase-3

Thomas A. Engler, James R. Henry, Sushant Malhotra et al. · Journal of Medicinal Chemistry · 2004 · 102 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Stereoselective syntheses of substituted pterocarpans with anti-HIV activity, and 5-aza-/5-thia-pterocarpan and 2-aryl-2,3-dihydrobenzofuran analogues

Thomas A. Engler, Kenneth O. LaTessa, Rajesh Iyengar et al. · Bioorganic & Medicinal Chemistry · 1996 · 100 citations

Pharmacy, Chemistry, Medicinal Chemistry +9